Bristol Myers Squibb

Pharmaceuticals
BMY
$ 76 (1.3)%
Share price
$ 162 bn
Market Cap
$ 195 bn
Enterprise Value

Carbon footprint

1.4 Ton
GHG emissions per $ 1 mln investment
0.05x the weighted average for S&P 500
FY2020
How is this calculated?
-2.1%
YOY change in GHG emissions
Weaker than the -8.7% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

-5%
Proj. YOY change in GHG emissions (Scope 1 + 2)
In line with the -5.1% weighted average for S&P 500
FY2021
How is this calculated?

Bristol Myers Squibb aims to achieve net zero for Scope 1 + 2 by 2040


This target has not been verified as science based according to SBTi
Bristol Myers Squibb's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Bristol Myers Squibb's GHG emissions (market-based) (Kt of CO2e)
Bristol Myers Squibb's Carbon intensity (Tons per 1 USDm)

Bristol Myers Squibb's carbon footprint

Bristol Myers Squibb reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 278 Kt (-6 /-2.1% y-o-y). Also positively, carbon intensity dropped to 6.5 t (-4.4 /-40.4% y-o-y).

Bristol Myers Squibb's Scope 3 emissions tumbled to 12 Kt (-44 /-78.7% y-o-y). This is a higher rate of decline than over the period since 4Q'16 (-31.1% CAGR).

The company is committed to achieving net zero for Scope 1 + 2 by 2040, which translates into the estimated reduction of -14 Kt per annum over the period of FY2021 - FY2040. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...
Copyright © 2022 Exerica. All rights reserved.